SLC5A2 and type 2 diabetes mellitus: Using Taiwan’s comprehensive National Health Insurance Research Database (NHIRD), which provides longitudinal medication and diagnostic data for nearly the entire population [18], we aimed to investigate whether the use of SGLT2 inhibitors (SGLT2i) is associated with the risk of developing sensorineural hearing loss among patients with type 2 diabetes mellitus (T2DM).